+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using IDH1 mouse mAb against HepG2 (1), NIH/3T3 (2), C2C12 (3), COS7 (4), and SW480 (5) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using IDH1 mouse mAb (green) and negative control (red).    

  
  

The IDH1 antibody is a key tool in cancer research and diagnostics, primarily targeting isocitrate dehydrogenase 1 (IDH1), a metabolic enzyme involved in cellular energy production and redox balance. Wild-type IDH1 catalyzes the conversion of isocitrate to α-ketoglutarate (α-KG) in the cytoplasm. However, somatic mutations in the IDH1 gene, particularly the R132H variant, are prevalent in certain cancers, including gliomas, acute myeloid leukemia (AML), and chondrosarcomas. Mutant IDH1 gains a neomorphic activity, producing the oncometabolite D-2-hydroxyglutarate (D-2-HG), which disrupts cellular epigenetics and promotes tumorigenesis.

IDH1 antibodies are widely used in immunohistochemistry (IHC) to detect IDH1 R132H mutations, aiding in the classification and prognosis of gliomas. Tumors with IDH1 mutations typically exhibit better prognosis compared to IDH-wildtype counterparts, influencing therapeutic strategies. Additionally, these antibodies support research into metabolic reprogramming, tumor microenvironment interactions, and therapeutic targeting of mutant IDH1. Their specificity for mutant versus wild-type protein makes them critical for both diagnostic accuracy and mechanistic studies in cancer biology.